Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.

Tumori - 1 Dec 2024

Leporati Rita, Miliziano Daniela, Beninato Teresa, Mazzeo Laura, Manglaviti Sara, Brambilla Marta, Occhipinti Mario, Prelaj Arsela, Proto Claudia, Lo Russo Giuseppe

Abstract excerpt

INTRODUCTION: Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With the increasing number of target therapies available, the optimal sequence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbazoles

Share to Lactams

Share to Lactams, Macrocyclic

Share to Organophosphorus Compounds

Share to Piperidines

Share to Pyrazoles

Source

Identifiers

PMID: 38623748
DOI: 10.1177/03008916241246659

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.PMID 38623748Read ↗

Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.Semantic proximity Read ↗

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.Semantic proximity Read ↗

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancerSemantic proximity Read ↗

A Novel ALK Gene Mutation and Its Response to Second-Generation TKIs: a Case Report and Literature ReviewSemantic proximity Read ↗

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung CancerSemantic proximity Read ↗

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read ↗

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the LiteratureSemantic proximity Read ↗

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.